课题基金 / 基金详情

ESOMEPRAZOLE IN PATIENTS WITH DIARRHEA PREDOMINANT IBS OR FUNCTIONAL DIARRHEA

ESOMEPRAZOLE IN PATIENTS WITH DIARRHEA PREDOMINANT IBS OR FUNCTIONAL DIARRHEA
埃索美拉唑治疗腹泻为主的肠易激综合征或功能性腹泻患者
批准号:
7377494
负责人:
YEHUDA RINGEL
金额:
$1.54万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-01 至 2006-11-30

项目摘要

项目成果

YEHUDA RINGEL的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。本研究的目的是确定埃索美拉唑40 mg qd是否能改善腹泻型IBS或功能性腹泻患者的胃肠(GI)症状。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the research study is to determine if Esomeprazole 40 mg qd will improve gastronintestinal (GI) symptoms in patients with diarrhea predominant-IBS or functional diarrhea.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fecal Microflora in Irritable Bowel Syndrome: Characterization & Significance
Fecal Microflora in Irritable Bowel Syndrome (IBS): Characterization and Signific
CLINICAL TRIAL: PROBIOTIC BACTERIA IN PATIENTS WITH IBS, FUNCTIONAL DIARRHEA, OR
YOGURT DRINK CONTAINING BIFIDOBACTERIUM LACTIS (BB12) FUNCTIONAL GASTROINTESTINL
海外基金